Despite the weak performance of Faes’ lynchpin drug, Bilastine, the top line grew by 7%, thanks to the strong performance in Spain and the Diafarm franchisee, and the acquisition of BCN. Also, the bottom line outpaced revenue growth on the back of higher milestone income and lower operating expenses. Capacity expansion is welcome news, both strategically and financially. In our view, Hidroferol’s success in the COVID-19 space could result in positive momentum for the stock.
03 Mar 2021
Bilastine weighed on FY20; capacity expansion to cater underlying demand
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Bilastine weighed on FY20; capacity expansion to cater underlying demand
- Published:
03 Mar 2021 -
Author:
Rishabh Kochar | Amandeep Goyal -
Pages:
3
Despite the weak performance of Faes’ lynchpin drug, Bilastine, the top line grew by 7%, thanks to the strong performance in Spain and the Diafarm franchisee, and the acquisition of BCN. Also, the bottom line outpaced revenue growth on the back of higher milestone income and lower operating expenses. Capacity expansion is welcome news, both strategically and financially. In our view, Hidroferol’s success in the COVID-19 space could result in positive momentum for the stock.